Stockscreener 앱 받기
92.40
1.63%
-1.46
전일 마감가:
$93.86
열려 있는:
$93.65
하루 거래량:
966.74K
Relative Volume:
0.08
시가총액:
$160.53B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
25.74
EPS:
3.5895
순현금흐름:
$7.40B
1주 성능:
+0.69%
1개월 성능:
-11.21%
6개월 성능:
-25.80%
1년 성능:
-29.25%
1일 변동 폭
$92.26
$93.72
1주일 범위
$90.72
$94.79
52주 변동 폭
$90.72
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
92.38 | 163.10B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
313.38 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.06 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.33 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
80.96 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Middle East and Africa Continuous Glucose Monitoring Market Forecast and Company Analysis Report 2026-2034 Featuring Dexcom, Medtronic, Senseonics, Abbott Diabetes Care, and GlySens - GlobeNewswire Inc.
Abbott’s FDA-Cleared Ultreon 3.0 Redefines Imaging in Coronary Interventions - The Indian Practitioner
Major Insider Move Signals Growing Confidence at Abbott Laboratories - TipRanks
Abbott (NYSE: ABT) awards director 2,286 restricted stock units - Stock Titan
Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding - Stock Titan
Abbott Laboratories director Daniel Starks buys $926,537 in shares - Investing.com
Abbott Laboratories director Daniel Starks buys $926,537 in shares By Investing.com - Investing.com India
[Form 4] ABBOTT LABORATORIES Insider Trading Activity - Stock Titan
Abbott Laboratories (NYSE: ABT) director receives 2,286-share restricted stock unit award - Stock Titan
Abbott Laboratories (ABT) director gets RSU and option awards - Stock Titan
Abbott Laboratories (NYSE: ABT) grants shares and stock options to director - Stock Titan
Abbott (NYSE: ABT) director Darren McDew receives 2,286-share RSU award - Stock Titan
Abbott Laboratories (NYSE: ABT) director gets 2,286-share stock unit grant - Stock Titan
Director at Abbott Laboratories (NYSE: ABT) awarded 2,286 share-linked units - Stock Titan
Abbott Laboratories (NYSE: ABT) grants director 2,286 RSUs - Stock Titan
Director at Abbott Laboratories (NYSE: ABT) receives 2,286-share stock grant - Stock Titan
Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS
Abbott Laboratories (NYSE: ABT) director awarded 2,286 RSUs - Stock Titan
Steady action for Abbott Laboratories stock as price tests resistance levels near $93.37 - Traders Union
Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Exact Sciences Acquisition - Quiver Quantitative
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report - GlobeNewswire
Abbott gains FDA clearance, CE mark approval for AI-powered imaging platform - Cardiovascular Business
Abbott (ABT) Gains FDA and CE Approval for Ultreon 3.0 Software - GuruFocus
How to Pick a Healthcare Stock That Can Weather Any Market - The Globe and Mail
HbA1c Analyzer Market to Reach USD 1.6 Billion in 2026, Led - openPR.com
Abbott receives FDA clearance, CE Mark for AI imaging platform By Investing.com - Investing.com Canada
Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform - Abbott MediaRoom
Abbott's AI tool pairs 1-second artery scans with stent guidance - Stock Titan
Late-Breaking AFib Data on Pulsed Field Ablation Could Be A Game Changer For Abbott (ABT) - simplywall.st
Point of Care Diagnostics Market | Abbott Laboratories, BD, Danaher Corp, Nova Biomedical Corporation etc. - openPR.com
Top Abbott Executive Makes Bold Insider Move at Abbott Laboratories - TipRanks
Abbott Laboratories (ABT) Announces New Board Member and Adoptio - GuruFocus
Proposed RSU sales by ABT insider via UBS (NYSE: ABT) on 04/27/2026 - Stock Titan
Abbott Laboratories EVP and CFO Philip Boudreau buys $201,300 in stock By Investing.com - Investing.com South Africa
Abbott (NYSE: ABT) CFO adds 2,200 shares in open-market buy - Stock Titan
Abbott Expands Board and Enhances Equity Incentive Programs - TipRanks
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott (NYSE: ABT) holders back 2026 stock plan, expand board - Stock Titan
Abbott's Strong AFib, Cardiac Device Data Fuels Heart-Rhythm Device Buzz - Benzinga
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
Abbott (ABT) Reports Promising Data on Heart Treatment Technologies - GuruFocus
Assessing Abbott (ABT) Valuation After New Cardiac Trial Results And Recent Share Price Pullback - simplywall.st
Teachers Retirement System of The State of Kentucky Trims Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Vanguard Group Inc. - MarketBeat
Commentary: There is a hidden cost to the Abbott verdict for premature babies - Daily Republic
Concurrent Investment Advisors LLC Purchases 17,137 Shares of Abbott Laboratories $ABT - MarketBeat
Why Abbott Laboratories stock tumbled on Thursday - MSN
Cardiac treatment advancements see Abbott Laboratories stock down 1.44% amid oversold signals and bearish pressure - Traders Union
Abbott Laboratories Q1 2026 Earnings: $2B CGM Quarter, 65% Upside Priced In - TIKR.com
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 - Abbott MediaRoom
4 new studies test Abbott devices for irregular heartbeats - Stock Titan
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
자본화:
|
볼륨(24시간):